Opko Health Inc. (OPK) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q/A for Q2 FY2026, filed Aug 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OPK SEC filings page.
Opko Health Inc. (OPK) reported $587.9M in revenue over the twelve months to Jun 30, 2026, down 11.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
OPKO’s lightly indebted balance sheet cannot offset shrinking sales and persistent cash consumption from its operating model.
Gross margin recovered across the reported period from28.7% to33.9% , but operating margin remained-19.4% at the latest period. The pattern indicates that improvement at the gross-profit layer has not yet covered the company’s operating cost base.
Revenue fell to
Debt-to-equity was just 0.0x and the current ratio was 4.0x, so near-term obligations are not being funded through heavy borrowing. Reported liquidity equaled 25.4 months of the latest annual operating outflow, providing a present balance-sheet buffer even as accumulated losses have reduced total equity over time.
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Opko Health Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Opko Health Inc. has an operating margin of -19.4%, meaning the company loses $19 on every $100 of revenue. This results in a profitability score of 23/100. This is up from -21.3% the prior year.
Opko Health Inc.'s revenue declined 14.9% year-over-year, from $713.1M to $606.9M. This contraction results in a growth score of 5/100.
Opko Health Inc. carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.97, Opko Health Inc. holds $3.97 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 87/100.
Opko Health Inc.'s operations used $178.5M of cash, and capex of $12.3M added to the outflow, for a free cash flow shortfall of $190.8M. This results in a cash flow score of 7/100.
Opko Health Inc. scores -0.29, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.1B) relative to total liabilities ($664.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Opko Health Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Key Financial Metrics
Earnings & Revenue
Opko Health Inc. generated $163.6M in revenue in Q2 2026. This represents an increase of 4.3% from the same quarter a year earlier. Against the prior quarter it is up 31.7%.
Opko Health Inc.'s EBITDA was $15.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 141.8% from the same quarter a year earlier. Against the prior quarter it is up 153.6%.
Opko Health Inc. reported -$8.4M in net income in Q2 2026. This represents an increase of 94.3% from the same quarter a year earlier. Against the prior quarter it is up 84.7%.
Opko Health Inc. earned -$0.01 per diluted share (EPS) in Q2 2026. This represents an increase of 94.7% from the same quarter a year earlier. Against the prior quarter it is up 85.7%.
Cash & Balance Sheet
Opko Health Inc. recorded an outflow of $46.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 46.4% from the same quarter a year earlier. Against the prior quarter it is down 119.9%.
Opko Health Inc. held $300.8M in cash against $1.8M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Opko Health Inc.'s gross margin was 48.9% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 17.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.1 percentage points.
Opko Health Inc.'s operating margin was -4.3% in Q2 2026, reflecting core business profitability. This is up 34.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 36.8 percentage points.
Opko Health Inc.'s net profit margin was -5.1% in Q2 2026, showing the share of revenue converted to profit. This is up 89.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 39.0 percentage points.
Opko Health Inc.'s ROE was -0.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 10.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.8 percentage points.
Capital Allocation
Opko Health Inc. invested $33.2M in research and development in Q2 2026. This represents an increase of 9.3% from the same quarter a year earlier. Against the prior quarter it is up 13.6%.
Opko Health Inc. spent $13.0M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 28.7% from the same quarter a year earlier. Against the prior quarter it is up 173.1%.
Opko Health Inc. invested $3.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 8.5% from the same quarter a year earlier. Against the prior quarter it is up 63.9%.
OPK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q/A | Q1'2610-Q/A | Q4'2510-K | Q3'2510-K | Q2'2510-Q/A | Q1'2510-Q/A | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $163.6M+4.3% | $124.2M-17.2% | $148.5M-19.2% | $151.7M-12.6% | $156.8M-13.9% | $150.0M-13.7% | $183.6M+1.0% | $173.6M-2.8% |
| Cost of Revenue | $83.6M-22.2% | $78.4M-26.9% | N/A | $101.8M-23.8% | $107.4M-17.7% | $107.3M-18.5% | N/A | $133.5M |
| Gross Profit | $80.0M+62.0% | $45.8M+7.4% | N/A | $49.9M+24.3% | $49.4M-4.4% | $42.6M+1.3% | N/A | $40.1M |
| R&D Expenses | $33.2M+9.3% | $29.2M-5.3% | N/A | $30.1M+4.5% | $30.3M+26.0% | $30.8M+40.6% | N/A | $28.8M+48.0% |
| SG&A Expenses | $52.9M-11.2% | $48.6M-17.7% | N/A | $53.8M-45.2% | $59.6M-13.4% | $59.1M-15.8% | N/A | $98.2M+35.9% |
| Operating Income | -$7.0M+88.4% | -$51.0M+24.0% | N/A | $48.1M+171.5% | -$60.0M+2.7% | -$67.2M+6.0% | N/A | -$67.2M-4.3% |
| EBITDA | $15.4M+141.8% | -$28.8M+34.0% | N/A | $70.8M+264.6% | -$37.0M+1.5% | -$43.7M+4.3% | N/A | -$43.0M-12.5% |
| Interest Expense | $11.4M-83.8% | $10.9M-29.3% | N/A | $11.4M-34.6% | $70.3M+759.7% | $15.5M+101.2% | N/A | $17.4M+413.0% |
| Income Tax | -$5.0M+64.6% | -$6.1M-5.9% | N/A | $19.8M-15.9% | -$14.1M-4928.2% | -$5.8M-327.4% | N/A | $23.5M+287.3% |
| Net Income | -$8.4M+94.3% | -$54.8M+18.9% | -$31.3M-322.8% | $21.6M-13.1% | -$148.4M-1340.5% | -$67.6M+17.4% | $14.0M+121.1% | $24.9M+129.5% |
| EPS (Basic) | -$0.01+94.7% | -$0.07+30.0% | -$0.04-300.0% | $0.03-25.0% | -$0.19-1800.0% | -$0.10+16.7% | $0.02+122.2% | $0.04+136.4% |
| EPS (Diluted) | -$0.01+94.7% | -$0.07+30.0% | -$0.04 | $0.030.0% | -$0.19-1800.0% | -$0.10+16.7% | $0.01 | $0.03+127.3% |
| Diluted Shares (Avg) | 755M-4.2% | 759M+13.0% | N/A | 780M-21.9% | 788M+13.0% | 672M | N/A | 998M+32.8% |
OPK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q/A | Q1'2610-Q/A | Q4'2510-K | Q3'2510-K | Q2'2510-Q/A | Q1'2510-Q/A | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.8B-7.3% | $1.9B-12.8% | $1.9B-12.2% | $2.0B-11.6% | $2.0B-0.3% | $2.1B+7.8% | $2.2B+9.4% | $2.3B+9.7% |
| Current Assets | $500.2M-14.2% | $535.4M-27.4% | $581.9M-12.1% | $627.1M-0.4% | $583.3M+63.0% | $737.6M+88.5% | $662.1M+113.9% | $629.6M+76.3% |
| Cash & Equivalents | $300.8M+12.5% | $331.9M-22.6% | $364.4M-14.6% | $412.0M+3.0% | $267.3M+558.7% | $428.8M+466.9% | $426.6M+344.9% | $400.1M+188.6% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $61.9M-6.8% | $64.4M+0.6% | $65.8M+15.9% | $65.0M+9.3% | $66.3M+10.3% | $64.0M+7.8% | $56.8M-13.5% | $59.4M-13.9% |
| Accounts Receivable | $81.9M-17.6% | $79.6M-17.2% | $90.3M-23.5% | $94.6M-11.3% | $99.4M-5.6% | $96.2M-13.7% | $118.0M-4.3% | $106.6M-9.3% |
| Long-Term Investments | $40.2M+208.3% | $10.5M-17.4% | $14.2M-74.0% | $13.4M-86.7% | $13.0M-87.1% | $12.8M-68.9% | $54.6M+239.4% | $100.6M+419.2% |
| Goodwill | $481.5M-0.6% | $482.3M+1.2% | $484.3M-8.5% | $484.0M-9.7% | $484.2M-8.7% | $476.7M-10.2% | $529.3M-11.5% | $535.9M-9.9% |
| Total Liabilities | $645.3M-4.6% | $652.2M-20.1% | $664.0M-20.5% | $690.0M-19.1% | $676.1M+15.7% | $816.7M+13.2% | $834.8M+34.1% | $852.7M+39.3% |
| Current Liabilities | $149.4M-12.7% | $148.4M-49.8% | $146.7M-24.0% | $169.3M-20.0% | $171.2M-22.0% | $295.9M+44.8% | $193.1M-3.5% | $211.7M+5.5% |
| Non-Current Liabilities | $495.9M-1.8% | $503.8M-3.3% | $517.3M-19.4% | $520.7M-18.8% | $504.9M+38.3% | $520.8M+0.8% | $641.7M+51.9% | $641.0M+55.8% |
| Long-Term Debt | $1.8M-35.8% | $2.0M-29.2% | $2.3M-24.7% | $2.5M-28.9% | $2.8M-24.6% | $2.8M-29.8% | $3.0M-61.1% | $3.5M-55.5% |
| Total Equity | $1.2B-8.7% | $1.2B-8.2% | $1.3B-7.1% | $1.3B-7.0% | $1.3B-7.1% | $1.3B+4.7% | $1.4B-1.7% | $1.4B-2.8% |
| Retained Earnings | -$2.4B-3.2% | -$2.3B-10.0% | -$2.3B-10.9% | -$2.3B-8.7% | -$2.3B-8.4% | -$2.1B-1.9% | -$2.1B-2.6% | -$2.1B-6.9% |
OPK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q/A | Q1'2610-Q/A | Q4'2510-K | Q3'2510-K | Q2'2510-Q/A | Q1'2510-Q/A | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$43.5M+47.9% | -$19.3M+44.1% | -$25.9M+41.6% | -$34.6M+55.1% | -$83.4M-215.6% | -$34.6M+2.8% | -$44.4M-16.0% | -$77.1M-332.8% |
| Depreciation & Amortization | $22.4M-2.7% | $22.2M-5.5% | $22.4M-6.9% | $22.7M-5.9% | $23.0M-4.7% | $23.5M-9.0% | $24.0M-7.5% | $24.2M-7.7% |
| Stock-Based Compensation | $2.2M0.0% | $2.7M+4.5% | N/A | $3.0M+7.1% | $2.2M-15.4% | $2.6M+1.0% | N/A | $2.8M-12.5% |
| Capital Expenditures | $3.0M-8.5% | $1.8M-42.6% | $2.7M-50.7% | $3.1M-60.5% | $3.3M-54.5% | $3.2M-28.1% | $5.4M+79.1% | $7.9M+88.8% |
| Free Cash Flow | -$46.5M+46.4% | -$21.1M+44.0% | -$28.6M+42.6% | -$37.8M+55.6% | -$86.7M-157.6% | -$37.7M+5.7% | -$49.8M-20.6% | -$85.0M-394.1% |
| Investing Cash Flow | $15.5M+648.2% | -$1.8M-104.4% | -$2.0M-101.8% | $194.6M-21.4% | -$2.8M+60.4% | $40.5M+1022.1% | $116.0M+8279.6% | $247.8M+7036.8% |
| Financing Cash Flow | -$13.0M+83.6% | -$5.2M-28.2% | -$18.3M+54.7% | -$16.2M-107.9% | -$79.5M-3658.3% | -$4.0M-119.5% | -$40.5M-979.0% | $206.1M+9692.9% |
| Share Buybacks | $13.0M-28.7% | $4.8M | $13.5M-18.0% | $15.3M-35.7% | $18.3M | $0-100.0% | $16.5M | $23.8M |
Not reported in any period shown, so not listed: Dividends Paid.
OPK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q/A | Q1'2610-Q/A | Q4'2510-K | Q3'2510-K | Q2'2510-Q/A | Q1'2510-Q/A | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 48.9%+17.4pp | 36.8%+8.4pp | N/A | 32.9%+9.8pp | 31.5%+3.2pp | 28.4%+4.2pp | N/A | 23.1% |
| Operating Margin | -4.3%+34.0pp | -41.1%+3.7pp | N/A | 31.7%+70.4pp | -38.3%-4.4pp | -44.8%-3.6pp | N/A | -38.7%-2.6pp |
| Net Margin | -5.1%+89.5pp | -44.2%+0.9pp | -21.1%-28.7pp | 14.3%-0.1pp | -94.7%-89.0pp | -45.1%+2.0pp | 7.6%+44.2pp | 14.3%+61.6pp |
| Return on Equity | -0.7%+10.7pp | -4.5%+0.6pp | -2.5%-3.5pp | 1.7%-0.1pp | -11.5%-10.7pp | -5.1%+1.4pp | 1.0%+5.8pp | 1.8%+7.6pp |
| Return on Assets | -0.5%+7.1pp | -2.9%+0.2pp | -1.6%-2.3pp | 1.1%0.0pp | -7.5%-7.0pp | -3.2%+1.0pp | 0.6%+3.9pp | 1.1%+5.2pp |
| Current Ratio | 3.35-0.1x | 3.61+1.1x | 3.97+0.5x | 3.70+0.7x | 3.41+1.8x | 2.49+0.6x | 3.43+1.9x | 2.97+1.2x |
| Debt-to-Equity | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x |
| Asset Turnover | 0.090.0x | 0.070.0x | 0.080.0x | 0.080.0x | 0.080.0x | 0.070.0x | 0.080.0x | 0.080.0x |
| FCF Margin | -28.4%+26.9pp | -17.0%+8.1pp | -19.3%+7.9pp | -24.9%+24.1pp | -55.3%-36.8pp | -25.2%-2.1pp | -27.1%-4.4pp | -49.0%-65.1pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Opko Health Inc. OPK | FY2025 | $606.9M | N/A | N/A | $1.1B | 40/100 |
| Neogen Corp NEOG | FY2026 | $870.4M | -$7.9M | -0.9% | $2.8B | 27/100 |
| NeoGenomics, Inc. NEO | FY2025 | $727.3M | -$108.0M | -14.8% | $2.5B | 51/100 |
| GRAIL, Inc. GRAL | FY2025 | $147.2M | -$408.4M | N/A | $6.9B | 63/100 |
| Twist Bioscience Corporation TWST | FY2025 | $376.6M | -$77.7M | -20.6% | $13.6B | 50/100 |
| CareDx, Inc. CDNA | FY2025 | $379.8M | -$21.4M | -5.6% | $3.6B | 43/100 |
Where Opko Health Inc. Ranks
Frequently Asked Questions
What is Opko Health Inc.'s annual revenue?
Opko Health Inc. (OPK) reported $606.9M in total revenue for fiscal year 2025. This represents a -14.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Opko Health Inc.'s revenue growing?
Opko Health Inc. (OPK) revenue declined by 14.9% year-over-year, from $713.1M to $606.9M in fiscal year 2025.
What is Opko Health Inc.'s EBITDA?
Opko Health Inc. (OPK) had EBITDA of -$25.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Opko Health Inc. have?
As of fiscal year 2025, Opko Health Inc. (OPK) had $364.4M in cash and equivalents against $2.3M in long-term debt.
What is Opko Health Inc.'s gross margin?
Opko Health Inc. (OPK) had a gross margin of 33.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Opko Health Inc.'s operating margin?
Opko Health Inc. (OPK) had an operating margin of -19.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Opko Health Inc.'s free cash flow?
Opko Health Inc. (OPK) recorded an outflow of $190.8M in free cash flow during fiscal year 2025. This represents a 8.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Opko Health Inc.'s operating cash flow?
Opko Health Inc. (OPK) recorded an outflow of $178.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Opko Health Inc.'s total assets?
Opko Health Inc. (OPK) had $1.9B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Opko Health Inc.'s capital expenditures?
Opko Health Inc. (OPK) invested $12.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Opko Health Inc. spend on research and development?
Opko Health Inc. (OPK) invested $124.0M in research and development during fiscal year 2025.
What is Opko Health Inc.'s current ratio?
Opko Health Inc. (OPK) had a current ratio of 3.97 as of fiscal year 2025, which is generally considered healthy.
What is Opko Health Inc.'s debt-to-equity ratio?
Opko Health Inc. (OPK) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Opko Health Inc.'s P/E ratio?
Opko Health Inc. (OPK) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.1B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Opko Health Inc.'s price-to-sales ratio?
Opko Health Inc. (OPK) trades at 1.9x sales, its market capitalization divided by revenue of $587.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.1B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Opko Health Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Opko Health Inc. (OPK) held $378.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $178.5M over that year. Dividing the one by the other, the reported balance equals about 25 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Opko Health Inc.'s Altman Z-Score?
Opko Health Inc. (OPK) has an Altman Z-Score of -0.29, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Opko Health Inc.'s Piotroski F-Score?
Opko Health Inc. (OPK) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
How financially healthy is Opko Health Inc.?
Opko Health Inc. (OPK) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.